康泰生物
(300601)
| 流通市值：115.88亿 | | | 总市值：143.75亿 |
| 流通股本：9.00亿 | | | 总股本：11.17亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 325,769,377.7 | 336,114,637.08 | 169,306,957.52 | 257,299,273.36 |
| 交易性金融资产 | 2,032,100,525.42 | 1,809,393,519.18 | 1,711,429,779.45 | 1,688,805,102.78 |
| 应收票据及应收账款 | 2,625,000,740.17 | 2,739,990,577.39 | 2,752,419,009.27 | 2,583,739,375.47 |
| 其中：应收票据 | - | - | 357,853.43 | - |
| 应收账款 | 2,625,000,740.17 | 2,739,990,577.39 | 2,752,061,155.84 | 2,583,739,375.47 |
| 预付款项 | 18,155,638.96 | 16,060,953.83 | 56,837,275.62 | 21,330,313.78 |
| 其他应收款合计 | 34,903,342.56 | 6,443,842.62 | 11,428,741.37 | 11,159,660.73 |
| 存货 | 681,233,299.28 | 683,287,961.08 | 693,727,506.55 | 681,092,789.35 |
| 其他流动资产 | 493,465,254.63 | 614,194,671.42 | 561,438,256.18 | 751,304,870.09 |
| 流动资产合计 | 6,210,628,178.72 | 6,205,486,162.6 | 5,956,587,525.96 | 5,994,731,385.56 |
| 非流动资产: | | | | |
| 其他权益工具投资 | 1 | 1 | 1 | 1 |
| 投资性房地产 | 761,310,900.5 | 768,007,272.12 | 774,703,643.74 | 781,430,335.92 |
| 固定资产 | 4,132,429,192.25 | 4,192,085,511.28 | 4,315,720,162.56 | 4,253,398,683.13 |
| 在建工程 | 463,803,406.27 | 532,540,302.82 | 552,271,519.87 | 711,428,973.14 |
| 无形资产 | 554,092,099.75 | 489,531,369.67 | 497,264,162.1 | 467,900,623.1 |
| 开发支出 | 210,086,693.05 | 161,918,398.34 | 100,079,490.69 | 117,488,432.7 |
| 长期待摊费用 | 197,212,542.79 | 203,153,645.15 | 177,906,032.7 | 181,710,689.56 |
| 递延所得税资产 | 706,245,046.05 | 697,602,359.58 | 683,151,952.05 | 689,490,151.04 |
| 其他非流动资产 | 684,890,631.52 | 682,206,474.41 | 928,731,666.64 | 897,839,141.71 |
| 非流动资产合计 | 7,710,070,513.18 | 7,727,045,334.37 | 8,029,828,631.35 | 8,100,687,031.3 |
| 资产总计 | 13,920,698,691.9 | 13,932,531,496.97 | 13,986,416,157.31 | 14,095,418,416.86 |
| 流动负债: | | | | |
| 短期借款 | 11,005,802.5 | 11,005,802.5 | 11,005,157.78 | 0 |
| 应付票据及应付账款 | 522,733,907.08 | 556,135,604.38 | 571,064,424.06 | 708,248,201.19 |
| 其中：应付票据 | 28,921,220 | 34,534,420.68 | 48,601,852.44 | 116,399,324.35 |
| 应付账款 | 493,812,687.08 | 521,601,183.7 | 522,462,571.62 | 591,848,876.84 |
| 预收款项 | 23,596,632.13 | 16,629,610.4 | 7,377,647.21 | 8,622,552.16 |
| 合同负债 | 44,843,727.21 | 18,091,815.88 | 24,603,694.25 | 32,239,935.86 |
| 应付职工薪酬 | 30,506,408.14 | 31,428,133.18 | 54,065,828.45 | 55,133,950.36 |
| 应交税费 | 8,143,517.4 | 9,501,424.71 | 17,618,539.46 | 11,108,797.72 |
| 其他应付款合计 | 1,339,289,407.21 | 1,351,002,897.27 | 1,360,437,740.97 | 1,382,713,747.97 |
| 一年内到期的非流动负债 | 8,433,945.74 | 34,502,908.78 | 25,532,248.65 | 16,660,078.92 |
| 其他流动负债 | 3,641,783.14 | 2,307,167.36 | 3,148,313.92 | 957,071.16 |
| 流动负债合计 | 1,992,195,130.55 | 2,030,605,364.46 | 2,074,853,594.75 | 2,215,684,335.34 |
| 非流动负债: | | | | |
| 应付债券 | 1,932,272,354.25 | 1,911,051,669.61 | 1,890,333,837.48 | 1,869,842,009.68 |
| 预计负债 | 30,437,618.64 | 68,613,665.64 | 97,102,444.6 | 115,418,425.24 |
| 递延收益 | 253,774,485.13 | 255,704,144.23 | 258,296,638.08 | 262,213,774.52 |
| 递延所得税负债 | 2,378,719.11 | 2,382,028.05 | 671,670.57 | 671,670.57 |
| 非流动负债合计 | 2,218,863,177.13 | 2,237,751,507.53 | 2,246,404,590.73 | 2,248,145,880.01 |
| 负债合计 | 4,211,058,307.68 | 4,268,356,871.99 | 4,321,258,185.48 | 4,463,830,215.35 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,116,931,860 | 1,116,930,267 | 1,116,929,755 | 1,116,929,375 |
| 其他权益工具 | 511,028,621.07 | 511,035,012.28 | 511,037,083.03 | 511,038,616.92 |
| 资本公积 | 5,511,704,073.65 | 5,511,675,137.69 | 5,511,665,861.23 | 5,511,659,067.57 |
| 其他综合收益 | -304,134.45 | -259,436.98 | -242,690.87 | -206,750.32 |
| 盈余公积 | 364,998,253.51 | 364,998,253.51 | 364,998,253.51 | 364,998,253.51 |
| 未分配利润 | 2,183,583,322.11 | 2,138,618,259.73 | 2,160,663,751.3 | 2,127,324,728.65 |
| 归属于母公司股东权益合计 | 9,687,941,995.89 | 9,642,997,493.23 | 9,665,052,013.2 | 9,631,743,291.33 |
| 少数股东权益 | 21,698,388.33 | 21,177,131.75 | 105,958.63 | -155,089.82 |
| 股东权益合计 | 9,709,640,384.22 | 9,664,174,624.98 | 9,665,157,971.83 | 9,631,588,201.51 |
| 负债和股东权益合计 | 13,920,698,691.9 | 13,932,531,496.97 | 13,986,416,157.31 | 14,095,418,416.86 |
| 公告日期 | 2026-10-27 | 2026-08-22 | 2026-04-22 | 2026-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |